CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 71 enrolled
Drug / intervention
Genistein +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00287690
NCT00287690Phase 3Completed
CompareCT.gov

The Effect of Genistein (Supro®) on Coronary Artery Diameter and Blood Flow in Men and Women With Coronary Heart Disease

Imperial College London·interventional·Posted Feb 7, 2006·Updated Aug 5, 2019

In Brief

A Phase 3 clinical trial evaluating Genistein and Placebo for Coronary Artery Disease. Completed, enrolled 71 participants across 1 site.

Detailed Summary

The aim of this study is to investigate the effect of genistein administration on coronary arteries in humans. We will measure the size of a coronary artery and the speed and amount of blood flow in response after subjects have ingested Supro® drinks (a soy protein drink containing genistein).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 7, 2006
Enrollment StartOct 1, 1999
Primary CompletionAug 18, 2003
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 20.4 years ago

Interventions

Genisteindrug

Drink taken once daily

Placebodrug

Drink taken once daily